About The Study: The results of this comparative effectiveness research study suggest that sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a reduced risk of moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations compared with dipeptidyl peptidase 4 inhibitors in adults with type 2 diabetes and active COPD. This may inform prescribing of glucose-lowering medications among patients with type 2 diabetes and active COPD.
Corresponding Author: To contact the corresponding author, Elisabetta Patorno, MD, DrPH, email epatorno@bwh.harvard.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2024.7811)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.7811?guestAccessKey=fdd29a59-a219-4e07-83c0-78ab5ed08c4a&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=021025
JAMA Internal Medicine